I would support as well what Jeff has just mentioned, because right now the current system we have focuses only on pre-marketing surveillance, not post-marketing, although there is a little bit of effort there, but not as much, and as Manon mentioned earlier, because there are only a small number of patients who are exposed to the medications pre-marketing, we have limited information.
It seems that progressive licensing will be able to address some of the failures of the current system. We will be able to address issues related to adverse reactions more quickly if we have a system, however that will work. And again, it remains to be determined how exactly we are going to proceed with this progressive licensing, but we will be able to identify reactions sooner and be able to react sooner.